Background: Epithelial basement membrane dystrophy (EBMD) is by far the most common corneal dystrophy. In this study, we used a newly developed method of immunofluorescence staining and imaging to study the entire corneal nerve architecture of a donor with unilateral EBMD. Method: Two fresh eyes from a 56-year-old male donor were obtained; the right eye of the donor was diagnosed with EBMD and the left was normal. After slit lamp examination, the corneas were immunostained with anti-β-tubulin III antibody. Images were recorded by a fluorescent microscope equipped with a Photometrics digital camera using MetaVue imaging software. Results: The left cornea appeared normal as observed by slit lamp and stereomicroscope, but the right eye had numerous irregular geographic patches in the basement membrane. Immunofluorescence showed no difference in the stromal nerve distribution between the 2 eyes, but there were areas without innervations in the EBMD cornea. Subbasal nerve fibers also showed tortuous courses and fewer divisions. There was a significant decrease in the density of subbasal nerve fibers and the number of terminals in the right eye. Conclusion: We show for the first time detailed nerve architecture in an EBMD cornea. Our results suggest that EBMD-induced abnormalities of basement membrane altered epithelial nerve architecture and decreased nerve density, contributing to the pathology of the disease.

Keywords:
Epithelial basement membrane dystrophy, Corneal innervations, Immunofluorescence of corneal nerves, Recurrent erosion syndrome
1.
Vogt A: Lehrbuch und Atlas der Spaltlampenmikroskopie des lebenden Auges. Berlin, Springer, 1930, part 1, pp 264–265.
2.
Cogan DG, Donaldson DD, Kuwabara T, Marshall D: Microcystic dystrophy of the corneal epithelium. Trans Am Ophthalmol Soc 1964;62:213–225.
3.
Guerry D 3rd: Observations on Cogan’s microcystic dystrophy of the corneal epithelium. Trans Am Ophthalmol Soc 1965;63:320–334.
4.
Rodrigues MM, Fine BS, Laibson PR, Zimmermann LE: Disorders of the corneal epithelium. A clinicopathologic study of dot, geographic, and fingerprint patterns. Arch Ophthalmol 1974;92:475–482.
5.
Werblin TP, Hirst LW, Stark WJ, et al: Prevalence of map-dot-fingerprint changes in the cornea. Br J Ophthalmol 1981;65:401–409.
6.
Ghosh M, McCulloch C: Recurrent corneal erosion, microcystic epithelial dystrophy, map configurations and fingerprint lines in the cornea. Can J Ophthalmol 1986;21:246–252.
7.
Reidy JJ, Paulus MP, Gona S: Recurrent erosions of the cornea: epidemiology and treatment. Cornea 2000;19:767–771.
8.
Cogan DG, Kuwabara T, Donaldson DD, Collins E: Microcystic dystrophy of the cornea: a partial explanation for its pathogenesis. Arch Ophthalmol 1974;92:470–474.
9.
Ehlers N, Møller HU: Pathology and pathomechanisms of epithelial microcystic and basement membrane abnormalities of the cornea. Acta Ophthalmol (Copenh) 1988;66:318–326.
10.
Tripathi RC, Bron AJ: Cystic disorders of the corneal epithelium. II. Pathogenesis. Br J Ophthalmol 1973;57:376–390.
11.
Fogle JA, Kenyon KR, Stark WJ, Green WR: Defective epithelial adhesion in anterior corneal dystrophies. Am J Ophthalmol 1975;79:925–940.
12.
Laibson PR: Microcystic corneal dystrophy. Trans Am Ophthalmol Soc 1976;74:488–531.
13.
Brodrick JD, Dark AJ, Peace GW: Fingerprint dystrophy of the cornea: a histologic study. Arch Ophthalmol 1974;92:483–489.
14.
Kaufman HE, Clower JW: Irregularities of Bowman’s membrane. Am J Ophthalmol 1966;61:227–230.
15.
Laibson PR, Krachmer JHP: Familial occurrence of dot (microcystic), map, fingerprint dystrophy of the cornea. Invest Ophthalmol Vis Sci 1975;14:397–399.
16.
Fogle JA, Kenyon KR, Stark WJ, Green WR: Defective epithelial adhesion in anterior corneal dystrophies. Am J Ophthalmol 1975;79:925–940.
17.
Brown N, Bron A: Recurrent erosion of the cornea. Br J Ophthalmol 1976;60:84–96.
18.
Kenyon KR: Recurrent corneal erosion: pathogenesis and therapy. Int Ophthalmol Clin 1979;19:169–195.
19.
Aitken DA, Zeidoon AB, Lee WR: Ultrastructural study of the corneal epithelium in the recurrent erosion syndrome. Br J Ophthalmol 1995;79:282–289.
20.
Müller LJ, Marfurt CF, Kruse F, Tervo TM: Corneal nerves: structure, content and function. Exp Eye Res 2003;76:521–542.
21.
Lambiase A, Bonini S, Micera A, et al: Expression of nerve growth factor receptors on the ocular surface in healthy subjects and during manifestation of inflammatory diseases. Invest Ophthalmol Vis Sci 1998;39:1272–1275.
22.
Akhtar S, Bron AJ, Meek KM, and Voon LW: Clinical and ultrastructural findings in mare’s tail lines of the corneal epithelium. Br J Ophthalmol 2004;88:864–867.
23.
Rosenberg ME, Tervo TM, Petroll WM, Vesaluoma MH: In vivo confocal microscopy of patients with corneal recurrent erosion syndrome or epithelial basement membrane dystrophy. Ophthalmology 2000;107:565–573.
24.
Cavanagh HD, Petroll WM, Alizadeh H, et al: Clinical and diagnostic use of in vivo confocal microscopy in patients with corneal disease. Ophthalmology 1993;100:1444–1454.
25.
Kaufman SC, Beuerman RW, Kaufman HE: Diagnosis of advanced Fuchs’ endothelial dystrophy with the confocal microscope. Am J Ophthalmol 1993;116:652:653.
26.
Mustonen RK, McDonald MB, Srivannaboon S, et al: In vivo confocal microscopy of Fuchs’ endothelial dystrophy. Cornea 1998;17:493–503.
27.
Hernández-Quintela E, Mayer F, Dighiero P, et al: Confocal microscopy of cystic disorders of the corneal epithelium. Ophthalmology 1998;105:631–636.
28.
Labbé A, Nicola RD, Dupas B, et al: Epithelial basement membrane dystrophy: evaluation with the HRT II Rostock Cornea Module. Ophthalmology 2006;113:1301–1308.
29.
He J, Bazan NG, Bazan HE: Mapping the entire human corneal nerve architecture. Exp Eye Res 2010;91:513–523.
30.
He J, Bazan HE: Mapping the nerve architecture of diabetic human corneas. Ophthalmology 2012;119:956–964.
31.
Weiss JS, Moller HU, Lisch W, et al: The IC3D classification of the corneal dystrophies. Cornea 2008;27(suppl 2):S1–S42.
32.
Dastgheib KA, Clinch TE, Manche EE, et al: Sloughing of corneal epithelium and wound healing complications associated with laser in situ keratomileusis in patients with epithelial basement membrane dystrophy. Am J Ophthalmol 2000;130:297–303.
33.
Mclean EN, MacRae SM, Rich LF: Recurrent erosion: treatment by anterior stromal puncture. Ophthalmology 1986;93:784–788.
34.
Buxton JN, Constad WH: Superficial epithelial keratectomy for map-dot-fingerprint corneal dystrophy. Ann Ophthalmol 1987;19:92–96.
35.
Hykin PG, Foss AE, Pavesio C, Dart JK: The natural history and management of recurrent corneal erosion: a prospective randomized trial. Eye 1994;8(pt 1):35–40.
36.
Dursun D, Kim MC, Solomon A, et al: Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-doxycycline and corticosteroids. Am J Ophthalmol 2001;132:8–13.
37.
Itty S, Hamilton SS, Baratz KH, et al: Outcomes of epithelial debridement for anterior basement membrane dystrophy. Am J Ophthalmol 2007;144:288–289.
38.
Sridhar MS, Rapuano CJ, Cosar CB, et al: PTK versus diamond burr polishing of Bowman’s membrane in the treatment of recurrent corneal erosions associated with anterior basement membrane dystrophy. Ophthalmology 2002;109:674–679.
39.
Cavanaugh TB, Lind DM, Cutarelli PE, et al: Phototherapeutic keratectomy for recurrent erosion syndrome in anterior basement membrane dystrophy. Ophthalmology 1999;106:971–976.
40.
Cortina MS, He J, Li N, et al: Neuroprotectin D1 synthesis and corneal nerve regeneration after experimental surgery and treatment with PEDF plus DHA. Invest Ophthalmol Vis Sci 2010;51:804–810.
41.
Cortina MS, He J, Li N, et al: Recovery of corneal sensitivity, calcitonin gene-related peptide-positive nerves and increased wound healing induced by pigment epithelial-derived factor plus docosahexaenoic acid after experimental surgery. Arch Ophthalmol 2012;130:76–83.
42.
He J, Bazan HE: Omega-3 fatty acids in dry eye and corneal nerve regeneration after refractive surgery. Prostaglandins Leukot Essent Fatty Acids 2010;82:319–325.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.